2024
Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial
Blasiak A, Tan L, Chong L, Tadeo X, Truong A, Senthil Kumar K, Sapanel Y, Poon M, Sundar R, de Mel S, Ho D. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial. Npj Digital Medicine 2024, 7: 223. PMID: 39191913, PMCID: PMC11350179, DOI: 10.1038/s41746-024-01195-5.Peer-Reviewed Original ResearchArtificial intelligenceClinical decision support systemsDecision support systemIntegration of AIAI-enabled toolsWaldenstrom's macroglobulinemiaBruton tyrosine kinase inhibitor ibrutinibRare diseaseEnhance usersWaldenstrom's macroglobulinemia patientsKinase inhibitor ibrutinibSupport systemSecondary outcome measuresDiagnosed WMDigital health solutionsWM patientsInhibitor ibrutinibMacroglobulinemia patientsDosing recommendationsUsersManagement of rare diseasesClinical efficacyDevelopment of digital technologiesDose selectionPersonalized therapy
2023
Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment.
Senthil Kumar K, Miskovic V, Blasiak A, Sundar R, Pedrocchi A, Pearson A, Prelaj A, Ho D. Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment. American Society Of Clinical Oncology Educational Book 2023, 43: e390084. PMID: 37235822, DOI: 10.1200/edbk_390084.Peer-Reviewed Educational MaterialsConceptsDigital pathologyClinical oncology communityArtificial intelligence (AI)-based applicationsClinical oncologyDeployment of AIDomain of digital pathologyTreatment selectionOncology communityBiomarker developmentArtificial intelligenceImprove patient outcomesAI innovationRegimen optimizationModulating dosesStandard histologyPatient outcomes